While Knoll Pharmaceutical Co. markets its Meridia sibutramine neurotransmitter reuptake inhibitor to treat obesity, the active ingredients may have more widespread potential. To pursue that potential, Sepracor Inc. plans to develop both chiral isomers of desmethylsibutramine, which are the active forms of the two components of the racemic sibutramine. While both isomers are